DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
19 hedge funds and large institutions have $4.49M invested in DMK Pharmaceuticals Corporation Common Stock in 2014 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 10 reducing their positions, and 4 closing their positions.
5% less funds holding
Funds holding: 20 → 19 (-1)
21% less capital invested
Capital invested by funds: $5.65M → $4.49M (-$1.16M)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
80% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 10
90% less call options, than puts
Call options by funds: $8K | Put options by funds: $79K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$299K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$91.2K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$81.8K |
| 4 |
AIG
American International Group
New York
|
+$4.11K |
| 5 |
Morgan Stanley
New York
|
+$1.47K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GP
Grow Partners
San Diego,
California
|
-$522K |
| 2 |
SM
Scoggin Management
New York
|
-$422K |
| 3 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$403K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$33.4K |
| 5 |
Jane Street
New York
|
-$24.9K |
DMK Hedge Fund Activity: Q3 2014 in Review
19 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q3 2014, worth a combined $4.49M — down 21% from $5.65M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of DMK and 3 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 2 added.
The largest buyer was Marshall Wace, opening a new position worth an estimated $299K. The largest seller was Grow Partners, cutting an estimated $522K.
- 19 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q3 2014, down from 20 in Q2 2014.
- Funds reported $4.49M of DMK Pharmaceuticals Corporation Common Stock stock for Q3 2014, down 21% quarter-over-quarter.
- 3 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q3 2014 and 4 closed out, a net change of -1 holder.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q3 2014 was Marshall Wace, an estimated $299K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q3 2014 was Grow Partners, an estimated $522K sold.
Based on aggregated 13F filings for Q3 2014.